VEGFC抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: 231 cells, Primary antibody: P03627(VEGFC Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P03627(VEGFC Antibody) at dilution 1/5. (Original magnification: ×200)    

  
  

Vascular endothelial growth factor C (VEGFC) is a key signaling protein involved in lymphangiogenesis (formation of lymphatic vessels) and angiogenesis (formation of blood vessels). It primarily binds to tyrosine kinase receptors VEGFR-3 (FLT4) and VEGFR-2 (KDR), activating downstream pathways that regulate endothelial cell proliferation, migration, and survival. VEGFC plays critical roles in embryonic development, tissue repair, and pathological conditions such as cancer metastasis and lymphedema. Dysregulation of VEGFC is linked to tumor-associated lymphatic spread and inflammatory diseases.

VEGFC antibodies are immunodetection tools or therapeutic agents designed to specifically target VEGFC or its receptors. In research, they are widely used to inhibit VEGFC activity in vitro and in vivo, helping to elucidate its biological functions and interactions. Common applications include blocking ligand-receptor binding in mechanistic studies, suppressing lymphangiogenesis in disease models, and detecting VEGFC expression via techniques like Western blot, immunohistochemistry (IHC), or ELISA. Therapeutically, anti-VEGFC monoclonal antibodies or receptor inhibitors are under investigation for cancers (to curb metastasis) and lymphatic disorders. Clinical trials explore their potential in combination with anti-VEGFA therapies to overcome resistance in anti-angiogenic treatments. However, challenges remain in optimizing specificity, delivery, and minimizing off-target effects. Recent advancements include humanized antibodies and bispecific designs targeting multiple angiogenic pathways.